SCHEMBL2491983

SCHEMBL2491983

NC(=O)CC(=O)c1ccc(Cl)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.63
MAPT P10636 2/20 0.63
KDM4E B2RXH2 1/20 0.63
ALDH1A1 P00352 1/20 0.63
LMNA P02545 1/20 0.63
ERCC5 P28715 1/20 0.62
FEN1 P39748 1/20 0.62
GSK3B P49841 2/20 0.59
KMT2A Q03164 4/20 0.54
MEN1 O00255 3/20 0.54
CES2 O00748 1/20 0.50
CES1 P23141 1/20 0.50
AGTR1 P30556 1/20 0.50
RAB9A P51151 4/20 0.49
NPC1 O15118 3/20 0.49
TSHR P16473 2/20 0.48
CYP1A2 P05177 1/20 0.48
NFKB1 P19838 1/20 0.48
MAOB P27338 1/20 0.48
ALOX15 P16050 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11056976 0.92 KMT2A (0.60) L3MBTL1MAPTKDM4EALDH1A1LMNA
SCHEMBL24209665 0.89 MMP1 (0.60) L3MBTL1MAPTKDM4EALDH1A1LMNA
SCHEMBL600674 0.86 ERCC5 (0.72) L3MBTL1MAPTKDM4EALDH1A1LMNA
SCHEMBL28771856 0.82 ERCC5 (0.67) L3MBTL1MAPTKDM4EALDH1A1LMNA
SCHEMBL6820156 0.81 GSK3B (0.57) L3MBTL1MAPTKDM4EALDH1A1LMNA
SCHEMBL27745056 0.80 BLM (0.61) L3MBTL1MAPTKDM4EALDH1A1LMNA
SCHEMBL10789236 0.80 TSHR (0.55) MAPTKDM4EALDH1A1ERCC5FEN1
SCHEMBL4716770 0.80 ERCC5 (0.70) L3MBTL1MAPTKDM4EALDH1A1LMNA
SCHEMBL29113253 0.80 ERCC5 (0.64) L3MBTL1MAPTKDM4EALDH1A1LMNA
SCHEMBL10788517 0.79 NPC1 (0.55) L3MBTL1MAPTKDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4356971-A2 MODULATORS OF THE INTEGRATED STRESS PATHWAY Calico Life Sciences LLC (US) 2024-04-24 EP disclosed
CN-102256972-A Thiazolyl-benzimidazoles HOFFMANN LA ROCHE 2011-11-23 CN disclosed
EP-2379543-A2 THIAZOLYL-BENZIMIDAZOLES F. Hoffmann-La Roche AG (CH) 2011-10-26 EP disclosed
US-8044213-B2 Thiazolyl-benzimidazoles HOFFMANN-LA ROCHE INC. (US) 2011-10-25 US disclosed
WO-2010121675-A2 THIAZOLYL-BENZIMIDAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO disclosed
US-20100160308-A1 Thiazolyl-Benzimidazoles CAI JIANPING 2010-06-24 US disclosed
US-7049271-B2 Phenyl-substituted 2-enamino-ketonitriles BAYER AKTIENGESELLSCHAFT (DE) 2006-05-23 US disclosed
US-20060100106-A1 Phenyl-substituted 2-enamino-ketonitriles FISCHER REINER 2006-05-11 US disclosed
US-20030220196-A1 Phenyl-substituted-2enamino-keto nitriles BAYER AKTIENGESELLSCHAFT (DE) 2003-11-27 US disclosed
EP-1286956-A1 PHENYL-SUBSTITUTED 2-ENAMINO-KETO NITRILES Bayer CropScience AG (DE) 2003-03-05 EP disclosed
US-4160095-A PROSTAGLANDINS; ANTIINFLAMMATORY AGENTS THE UPJOHN COMPANY (US) 1979-07-03 US disclosed
US-4157441-A PROSTAGLANDINS, ANTIINFLAMMATORY AGENTS THE UPJOHN COMPANY (US) 1979-06-05 US disclosed
US-4151351-A PROSTAGLANDINS, ANTIINFLAMMATORY THE UPJOHN COMPANY (US) 1979-04-24 US disclosed
US-4131738-A 6-Hydroxy-PGE1 compounds THE UPJOHN COMPANY (US) 1978-12-26 US disclosed
US-4128713-A 6,7-Didehydro-PGI1 compounds THE UPJOHN COMPANY (US) 1978-12-05 US disclosed
US-4126744-A PROSTACYCLIN, MUSCLE STIMULANTS, PLATELET AGGREGATION INHIBITORS THE UPJOHN COMPANY (US) 1978-11-21 US disclosed
US-4112224-A PROSTAGLANDIN THE UPJOHN COMPANY (US) 1978-09-05 US disclosed
US-4109082-A PROSTACYCLIN ANALOGS; SMOOTH MUSCLE STIMULATORS THE UPJOHN COMPANY (US) 1978-08-22 US disclosed
US-4100192-A Inter-phenylene-PG amides THE UPJOHN COMPANY (US) 1978-07-11 US disclosed
US-4097489-A PROSTAGLANDINS THE UPJOHN COMPANY (US) 1978-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100106-A1 Phenyl-substituted 2-enamino-ketonitriles AR, KCNK4, KCNA1 L3MBTL1 1549/4885MAPT 2895/4885KDM4E 86/4885
US-20030220196-A1 Phenyl-substituted-2enamino-keto nitriles CYP1A1, CYP4X1, KCNK4 L3MBTL1 2952/4885MAPT 4153/4885KDM4E 128/4885
US-20100160308-A1 Thiazolyl-Benzimidazoles CYP3A7, CYP2C19, CYP3A5 L3MBTL1 3839/4885MAPT 1573/4885KDM4E 3163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.